Pharmaron Beijing Co., Ltd. (SHE:300759)

Market Cap	42.42B +10.2%
Revenue (ttm)	14.57B +14.7%
Net Income	1.69B -9.4%
EPS	0.95 -10.0%
Shares Out	1.83B
PE Ratio	26.44
Forward PE	19.69
Dividend	0.20 (0.80%)
Ex-Dividend Date	Jul 4, 2025

Volume	32,239,192
Open	26.73
Previous Close	25.02
Day's Range	24.73 - 26.73
52-Week Range	22.28 - 37.63
Beta	0.83
Analysts	Buy
Price Target	36.98 (+47.33%)
Earnings Date	Aug 24, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleot...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 25,088
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300759

Financial Performance

In 2025, Pharmaron Beijing's revenue was 14.10 billion, an increase of 14.82% compared to the previous year's 12.28 billion. Earnings were 1.66 billion, a decrease of -7.22%.